Search

Your search keyword '"Gardin, Claude"' showing total 5 results
Start Over Author "Gardin, Claude" Journal leukemia
5 results on '"Gardin, Claude"'

1. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia

Author

Pardieu, Bryann, Pasanisi, Justine, Ling, Frank, Dal Bello, Reinaldo, Penneroux, Justine, Su, Angela, Joudinaud, Romane, Chat, Laureen, Wu, Hsin Chieh, Duchmann, Matthieu, Sodaro, Gaetano, Chauvel, Clémentine, Castelli, Florence A., Vasseur, Loic, Pacchiardi, Kim, Belloucif, Yannis, Laiguillon, Marie-Charlotte, Meduri, Eshwar, Vaganay, Camille, Alexe, Gabriela, Berrou, Jeannig, Benaksas, Chaima, Forget, Antoine, Braun, Thorsten, Gardin, Claude, Raffoux, Emmanuel, Clappier, Emmanuelle, Adès, Lionel, de Thé, Hugues, Fenaille, François, Huntly, Brian J., Stegmaier, Kimberly, Dombret, Hervé, Fenouille, Nina, Lobry, Camille, Puissant, Alexandre, and Itzykson, Raphael

Published
2022
Full Text
View/download PDF

2. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

Author

Duchmann, Matthieu, Wagner-Ballon, Orianne, Boyer, Thomas, Cheok, Meyling, Fournier, Elise, Guerin, Estelle, Fenwarth, Laurène, Badaoui, Bouchra, Freynet, Nicolas, Benayoun, Emmanuel, Lusina, Daniel, Garcia, Isabel, Gardin, Claude, Fenaux, Pierre, Pautas, Cécile, Quesnel, Bruno, Turlure, Pascal, Terré, Christine, Thomas, Xavier, Lambert, Juliette, Renneville, Aline, Preudhomme, Claude, Dombret, Hervé, Itzykson, Raphael, and Cluzeau, Thomas

Published
2022
Full Text
View/download PDF

3. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

Author

Duployez, Nicolas, primary, Vasseur, Loïc, additional, Kim, Rathana, additional, Largeaud, Laëtitia, additional, Passet, Marie, additional, L’Haridon, Anaïs, additional, Lemaire, Pierre, additional, Fenwarth, Laurène, additional, Geffroy, Sandrine, additional, Helevaut, Nathalie, additional, Celli‑Lebras, Karine, additional, Adès, Lionel, additional, Lebon, Delphine, additional, Berthon, Céline, additional, Marceau-Renaut, Alice, additional, Cheok, Meyling, additional, Lambert, Juliette, additional, Récher, Christian, additional, Raffoux, Emmanuel, additional, Micol, Jean-Baptiste, additional, Pigneux, Arnaud, additional, Gardin, Claude, additional, Delabesse, Eric, additional, Soulier, Jean, additional, Hunault, Mathilde, additional, Dombret, Hervé, additional, Itzykson, Raphael, additional, Clappier, Emmanuelle, additional, and Preudhomme, Claude, additional

Published
2023
Full Text
View/download PDF

4. UBTFtandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

Author

Duployez, Nicolas, Vasseur, Loïc, Kim, Rathana, Largeaud, Laëtitia, Passet, Marie, L’Haridon, Anaïs, Lemaire, Pierre, Fenwarth, Laurène, Geffroy, Sandrine, Helevaut, Nathalie, Celli‑Lebras, Karine, Adès, Lionel, Lebon, Delphine, Berthon, Céline, Marceau-Renaut, Alice, Cheok, Meyling, Lambert, Juliette, Récher, Christian, Raffoux, Emmanuel, Micol, Jean-Baptiste, Pigneux, Arnaud, Gardin, Claude, Delabesse, Eric, Soulier, Jean, Hunault, Mathilde, Dombret, Hervé, Itzykson, Raphael, Clappier, Emmanuelle, and Preudhomme, Claude

Abstract

Tandem duplications (TDs) of the UBTFgene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF-TDs occur in about 3% of patients aged 18–60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF-TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1mutations (61%), FLT3-ITDs (51%) and trisomy 8 (29%). BM morphology frequently demonstrates dysmyelopoiesis albeit modulated by the co-occurrence of FLT3-ITD. UBTF-TD patients have lower complete remission (CR) rates (57% after 1 course and 76% after 2 courses of intensive chemotherapy [ICT]) than UBTF-wild-type patients. In patients enrolled in the ALFA-0702 study (n= 614 patients including 21 with UBTF-TD AML), the 3-year disease-free survival (DFS) and overall survival of UBTF-TD patients were 42.9% (95%CI: 23.4–78.5%) and 57.1% (95%CI: 39.5–82.8%) and did not significantly differ from those of ELN 2022 intermediate/adverse risk patients. Finally, the study of paired diagnosis and relapsed/refractory AML samples suggests that WT1-mutated clones are frequently selected under ICT. This study supports the recognition of UBTF-TD AML as a new AML entity in adults.

Published
2023
Full Text
View/download PDF

5. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

Author

Duchmann, Matthieu, primary, Wagner-Ballon, Orianne, additional, Boyer, Thomas, additional, Cheok, Meyling, additional, Fournier, Elise, additional, Guerin, Estelle, additional, Fenwarth, Laurène, additional, Badaoui, Bouchra, additional, Freynet, Nicolas, additional, Benayoun, Emmanuel, additional, Lusina, Daniel, additional, Garcia, Isabel, additional, Gardin, Claude, additional, Fenaux, Pierre, additional, Pautas, Cécile, additional, Quesnel, Bruno, additional, Turlure, Pascal, additional, Terré, Christine, additional, Thomas, Xavier, additional, Lambert, Juliette, additional, Renneville, Aline, additional, Preudhomme, Claude, additional, Dombret, Hervé, additional, Itzykson, Raphael, additional, and Cluzeau, Thomas, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results